Magle Chemoswed Holding Toekomstige groei

OM:MAGLE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	377	N/A	70	88	1
12/31/2025	350	N/A	51	73	1
12/31/2024	230	N/A	-3	15	1
9/30/2024	209	17	-9	13	N/A
6/30/2024	179	8	-11	7	N/A
3/31/2024	171	12	3	18	N/A
12/31/2023	171	12	0	15	N/A
9/30/2023	160	8	4	19	N/A
6/30/2023	158	9	1	18	N/A
3/31/2023	155	8	-6	15	N/A
12/31/2022	148	9	-4	12	N/A
9/30/2022	138	10	0	13	N/A
6/30/2022	136	10	-4	13	N/A
3/31/2022	133	7	5	17	N/A
12/31/2021	132	4	14	26	N/A
9/30/2021	137	3	-19	-4	N/A
6/30/2021	133	1	-2	7	N/A
3/31/2021	134	2	-21	-9	N/A
12/31/2020	142	2	-18	-6	N/A
9/30/2020	151	14	-48	-18	N/A
6/30/2020	140	8	-64	-25	N/A
3/31/2020	137	1	-52	-2	N/A
12/31/2019	132	1	-62	-7	N/A
12/31/2018	110	-3	-10	11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van MAGLE boven de spaarquote ( 1.1% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van MAGLE naar verwachting sneller zal groeien dan de markt Swedish

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van MAGLE naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: De omzet van MAGLE ( 27% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 0.01% per jaar).

Hoge groei-inkomsten: De omzet van MAGLE ( 27% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MAGLE naar verwachting over 3 jaar hoog zal zijn

Magle Chemoswed Holding Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 18%

Magle Chemoswed Holding AB (publ) (OM:MAGLE) completed the acquisition of Amniotics AB (publ) (OM:AMNI).

New minor risk - Share price stability

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 16%

Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality

First quarter 2024 earnings released: EPS: kr0.27 (vs kr0.27 in 1Q 2023)

Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%

Magle Chemoswed Holding AB (publ) (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (publ) (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Financial data availability

Magle Chemoswed Holding AB (publ) to Report Q4, 2024 Results on Feb 26, 2025

No independent directors

New minor risk - Share price stability

Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: kr0.87 (vs kr0.39 in FY 2021)

Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait

Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina

No independent directors

Magle Group Appoints New Chief Marketing and Innovation Officer

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding

Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN®

Magle Chemoswed Holding AB (publ) Announces Post Market Clinical Study for SmartPAN®

Magle Chemoswed Holding AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Investor sentiment deteriorated over the past week

No independent directors

Full year 2021 earnings released: EPS: kr0.39 (vs kr0.24 in FY 2020)

Magle Chemoswed Holding AB (publ), Annual General Meeting, May 17, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Full year 2020 earnings released: EPS kr0.24

Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: kr44.60

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Magle Chemoswed Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20 million.

New 90-day high: kr35.00

New 90-day high: kr34.60

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2020 Results on Apr 14, 2021

New 90-day high: kr33.50

New 90-day high: kr30.90

Magle Chemoswed Holding AB (Publ) Announces the Appointment of Joel Eklund as New Member of the Board

Magle Chemoswed Holding AB (publ) has completed an IPO in the amount of SEK 50 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven